You are here: Industry Insights > Bladder cancer

News List

Johnson & Johnson’s Balversa therapy finally gets full FDA approval Shem Oirere
March 05, 2024
The approval by the Federal Drug Agency of the bladder cancer therapy Balversa has taken a notch higher the search for more treatment options.
US clears BMS' Opdivo as first adjuvant therapy for bladder cancer firstwordpharma
August 23, 2021
Bristol Myers Squibb said Friday that the FDA has expanded Opdivo's (nivolumab) urothelial carcinoma (UC) indication to include adjuvant use in high-risk patients, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.
SMC approves Bavencio for bladder cancer pharmatimes
August 11, 2021
Merck and Pfizer’s Bavencio (avelumab) has been approved by the Scottish Medicines Consortium (SMC) for use via NHS Scotland as a first-line maintenance treatment for adult patients with locally advanced or metastatic urothelial carcinoma ...
Nonacus partners with Birmingham University to develop bladder cancer test pharmatimes
July 02, 2021
Genetic testing company Nonacus has partnered with the University of Birmingham to develop a non-invasive, urine test for bladder cancer.
Gilead’s Trodelvy scores accelerated approval in advanced bladder cancer pharmatimes
April 15, 2021
Gilead’s antibody drug conjugate (ADC) Trodelvy has received an accelerated approval from the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic urothelial cancer (UC), the most common form of bladder cancer.
Roche to withdraw US indication for Tecentriq in bladder cancer pharmaceutical-technolog
March 10, 2021
Roche is set to voluntarily withdraw the US indication for Tecentriq (atezolizumab) in prior platinum treated metastatic urothelial carcinoma (mUC, bladder cancer) following its consultation with the US Food and Drug Administration (FDA).
AZ withdraws Imfinzi indication in the US for advanced bladder cancer pharmatimes
February 23, 2021
AstraZeneca (AZ) has announced the voluntary withdrawal of its immunotherapy Imfinzi in its advanced bladder cancer indication in the US.
LIPAC Oncology Announces Completion of LiPax Trial for Bladder Cancer americanpharmaceuticalreview
September 24, 2020
LIPAC Oncology announced the successful completion of a Phase 2A marker lesion clinical trial designed to predict long-term (two-year) recurrence free survival rates in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer (NMIBC)...
Avelumab significantly improves advanced bladder cancer patient survival europeanpharmaceuticalreview
September 22, 2020
A Phase III trial concluded that avelumab is an effective maintenance therapy for patients with advanced or metastatic urothelial carcinoma, whose disease had not progressed after chemotherapy.
UK bladder cancer patients get early access to Bavencio pharmatimes
September 04, 2020
Merck and Pfizer’s Bavencio (avelumab) is now available under the UK's Early Access to Medicines Scheme (EAMS) giving some patients with bladder cancer the chance to receive treatment with the immunotherapy before its approval in Europe.

Previous page 1 2 3 4 5 Next page